Financials data is unavailable for this security.
View more
Year on year Caplin Point Laboratories Ltd grew revenues 15.50% from 14.67bn to 16.94bn while net income improved 21.48% from 3.76bn to 4.57bn.
| Gross margin | 58.72% |
|---|---|
| Net profit margin | 27.14% |
| Operating margin | 29.55% |
| Return on assets | 18.62% |
|---|---|
| Return on equity | 21.38% |
| Return on investment | 21.36% |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Caplin Point Laboratories Ltd fell by 388.60m. However, the company earned 3.18bn from its operations for a Cash Flow Margin of 18.79%. In addition the company used 3.20bn on investing activities and also paid 380.70m in financing cash flows.
| Cash flow per share | 73.42 |
|---|---|
| Price/Cash flow per share | 26.38 |
| Book value per share | 334.54 |
|---|---|
| Tangible book value per share | 333.01 |
More ▼
Balance sheet in INRView more
| Current ratio | 6.07 |
|---|---|
| Quick ratio | 5.07 |
| Total debt/total equity | 0.001 |
|---|---|
| Total debt/total capital | 0.0009 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 11.11% and 21.80%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.58% |
|---|---|
| Div growth rate (5 year) | 17.84% |
| Payout ratio (TTM) | 3.85% |
| EPS growth(5 years) | 20.85 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 18.36 |
More ▼
